Investment analysts at StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.

Charles Schwab Investment Management Inc. raised its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share ...

Intra-Cellular Therapies ITCI reported fourth-quarter 2024 loss of 16 cents per share, wider than the Zacks Consensus Estimate of a loss of 5 cents. The company had incurred a loss of 29 cents per ...

Below is Validea's guru fundamental report for INTRA-CELLULAR THERAPIES INC (ITCI). Of the 22 guru strategies we follow, ITCI rates highest using our Quantitative Momentum Investor model based on ...

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality ...